Cholesterol, lipoproteins and subclinical interstitial lung disease: the MESA study.

Podolanczuk AJ, Raghu G, Tsai MY, Kawut SM, Peterson E, Sonti R, Rabinowitz D, Johnson C, Barr RG, Hinckley Stukovsky K, Hoffman EA, Carr JJ, Ahmed FS, Jacobs DR, Watson K, Shea SJ, Lederer DJ
Thorax. 2017 72 (5): 472-474

PMID: 28130491 · PMCID: PMC5388565 · DOI:10.1136/thoraxjnl-2016-209568

We investigated associations of plasma lipoproteins with subclinical interstitial lung disease (ILD) by measuring high attenuation areas (HAA: lung voxels between -600 and -250 Hounsfield units) in 6700 adults and serum MMP-7 and SP-A in 1216 adults age 45-84 without clinical cardiovascular disease in Multi-Ethnic Study of Atherosclerosis. In cross-sectional analyses, each SD decrement in high density lipoprotein cholesterol (HDL-C) was associated with a 2.12% HAA increment (95% CI 1.44% to 2.79%), a 3.53% MMP-7 increment (95% CI 0.93% to 6.07%) and a 6.37% SP-A increment (95% CI 1.35% to 11.13%), independent of demographics, smoking and inflammatory biomarkers. These findings support a novel hypothesis that HDL-C might influence subclinical lung injury and extracellular matrix remodelling.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

MeSH Terms (16)

Aged Aged, 80 and over Biomarkers Cholesterol, HDL Coronary Artery Disease Cross-Sectional Studies Female Humans Lipoproteins Lung Diseases, Interstitial Male Matrix Metalloproteinase 7 Middle Aged Prospective Studies Pulmonary Surfactant-Associated Protein A Tomography, X-Ray Computed

Connections (1)

This publication is referenced by other Labnodes entities:

Links